Cara | $8,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
Certified by Founder
Lodge
Syremis Therapeutics
start up
- 19/12/2025
- Series A
- $165,000,000
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.
- Industry Biotechnology Research
- Website https://syremis.com/
- LinkedIn https://www.linkedin.com/company/syremis-therapeutics/
Related People
Elisabeth KoganFounder
Israel -
ND
CEO and Co-founder of Syremis Therapeutics, a Biotech company developing novel therapies for neuropsychiatric conditions.
Experienced Pharma executive with a successful track record of delivering innovation and growth in the pharmaceutical industry.
Passionate about bringing new solutions to patients to reduce suffering and improve quality of life.
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
TippingPoint Biosciences | $4,500,000 | (Apr 2, 2026)
Quantcore | $3,318,962 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)
Semarion | $3,800,000 | (Apr 2, 2026)
Via Separations | $36,000,000 | (Apr 2, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)